Corium International 10-Q 8 May 15 2015 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Mar. 31, 2015	7-May-15
Document and Entity Information
Entity Registrant Name	Corium International, Inc.
Entity Central Index Key	1594337
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-21
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		18,080,984
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Mar. 31, 2015	Sep. 30, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$33,660	$36,395
Accounts receivable	4,891	4,168
Unbilled accounts receivable	1,232	1,385
Inventories, net	2,961	2,592
Prepaid expenses and other current assets	686	1,292
Total current assets	43,430	45,832
Property and equipment, net	11,923	12,658
Debt financing costs, net	634	571
Intangible assets, net	6,741	6,683
TOTAL ASSETS	62,728	65,744
Current liabilities:
Accounts payable	2,588	2,512
Accrued expenses and other current liabilities	3,292	4,008
Long-term debt, current portion	54	107
Capital lease obligations, current portion	782	760
Recall liability, current portion	660	774
Deferred contract revenues, current portion	125	301
Total current liabilities	7,501	8,462
Long-term debt, net of current portion	48,970	38,155
Capital lease obligations, net of current portion	492	891
Recall liability, net of current portion	2,691	2,936
Deferred contract revenues, net of current portion	3,500	3,500
Total liabilities	63,154	53,944
Stockholders' equity (deficit):
Common stock; par value of $0.001 per share, 150,000,000 shares authorized; 18,072,866 and 18,003,883 shares issued and outstanding as of March 31, 2015 and September 30, 2014, respectively	18	18
Additional paid-in capital	115,792	114,117
Accumulated deficit	-116,236	-102,335
Total stockholders' equity (deficit)	-426	11,800
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$62,728	$65,744

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Sep. 30, 2014	Apr. 08, 2014
CONDENSED BALANCE SHEETS
Common stock, par value (in dollars per share)	$0.00	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000	150,000,000
Common stock, shares issued	18,072,866	18,003,883
Common stock, shares outstanding	18,072,866	18,003,883

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Revenues:
Product revenues	$7,632	$7,240	$14,171	$15,340
Contract research and development revenues	3,363	3,173	6,293	5,237
Other revenues	296	304	593	608
Total revenues	11,291	10,717	21,057	21,185
Costs and operating expenses:
Cost of product revenues	5,219	4,998	9,306	10,227
Cost of contract research and development revenues	4,510	3,911	8,227	7,448
Research and development expenses	3,980	1,267	8,177	2,128
General and administrative expenses	2,670	1,236	5,357	3,046
Amortization of intangible assets	162	131	323	261
(Gain) / loss on disposal and sale and leaseback of equipment		-32	7	-69
Total costs and operating expenses	16,541	11,511	31,397	23,041
Loss from operations	-5,250	-794	-10,340	-1,856
Interest income	4	1	6	3
Interest expense	-1,896	-1,780	-3,565	-3,804
Change in fair value of preferred stock warrant liability		-231		-274
Change in fair value of subordinated note embedded derivative liability		6,338		7,367
Income (loss) before income taxes	-7,142	3,534	-13,899	1,436
Income tax expense			2
Net income (loss) and comprehensive income (loss)	($7,142)	$3,534	($13,901)	$1,436
Net Income (loss) per share attributable to common stockholders, basic (in dollars per share)	($0.40)	$0.50	($0.77)	$0.03
Net Income (loss) per share attributable to common stockholders, diluted (in dollars per share)	($0.40)	$0.33	($0.77)	$0.02
Weighted average shares used in computing net income (loss) per share attributable to common stockholders, basic (in shares)	18,071,320	2,232,300	18,052,809	2,231,049
Weighted average shares used in computing net income (loss) per share attributable to common stockholders, diluted (in shares)	18,071,320	5,930,309	18,052,809	3,482,956

CONDENSED_STATEMENT_OF_STOCKHO

CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
In Thousands, except Share data, unless otherwise specified
Balance at Sep. 30, 2014	$18	$114,117	($102,335)	$11,800
Balance (in shares) at Sep. 30, 2014	18,003,883
Increase (Decrease) in Stockholders' Equity (Deficit)
Issuance of common stock under Employee Stock Purchase Plan		298		298
Issuance of common stock under Employee Stock Purchase Plan (in shares)	61,042
Issuance of common stock upon exercise of stock options		13		13
Issuance of common stock upon exercise of stock options (in shares)	7,941
Stock-based compensation expense		1,364		1,364
Net income (loss) and comprehensive income (loss)			-13,901	-13,901
Balance at Mar. 31, 2015	$18	$115,792	($116,236)	($426)
Balance (in shares) at Mar. 31, 2015	18,072,866

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) and comprehensive income (loss)	($13,901)	$1,436
Adjustments to reconcile net income (loss) to net cash used by operating activities:
Depreciation and amortization of property and equipment	1,102	1,054
(Gain) / loss on disposal and sale and leaseback of equipment	7	-69
Amortization of premium on modification of subordinated note		-286
Change in fair value of preferred stock warrant liability		274
Change in fair value of subordinated note embedded derivative liability		-7,367
Amortization of intangible assets	323	261
Noncash amortized issue costs on long-term debt and capital leases	87	171
Noncash amortized discount on long-term debt and capital leases	12	104
Stock-based compensation expense	1,364	250
Changes in operating assets and liabilities:
Accounts receivable	-723	-1,128
Unbilled accounts receivable	153	-848
Inventories, net	-369	1,469
Prepaid expenses and other current assets	606	454
Accounts payable	121	144
Accrued expenses and other current liabilities	70	1,412
Deferred contract revenues	-176	86
Recall liability	-359	-627
Long-term interest payable		823
Net cash used by operating activities	-11,683	-2,387
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	-419	-1,648
Proceeds from sale of equipment		12
Proceeds from repayment of notes receivable - related parties		100
Payments for patents and licensing rights	-381	-308
Net cash used by investing activities	-800	-1,844
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of long-term debt	10,000
Payment of transaction costs on issuance of common stock and long-term debt	-150	-1,832
Principal payments on long-term debt	-33	-452
Principal payments on capital lease obligations	-380	-525
Borrowings on bank line of credit		1,298
Payments on bank line of credit		-2,513
Proceeds from exercise of stock options	13	7
Proceeds from issuance of common stock under employee stock purchase plan	298
Net cash provided (used) by financing activities	9,748	-4,017
NET DECREASE IN CASH AND CASH EQUIVALENTS	-2,735	-8,248
CASH AND CASH EQUIVALENTS - Beginning of period	36,395	13,581
CASH AND CASH EQUIVALENTS - End of period	33,660	5,333
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	3,466	2,996
Cash paid for income taxes	1
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Property and equipment purchases included in accounts payable	154	38
Issuance of payment-in-kind notes in lieu of cash interest payments	786	647
Transaction costs associated with the initial public offering included in accrued liabilities		$1,161

Organization_Description_of_Bu

Organization, Description of Business, and Summary of Significant Accounting Policies	6 Months Ended
	Mar. 31, 2015
Organization, Description of Business, and Summary of Significant Accounting Policies
Organization, Description of Business, and Summary of Significant Accounting Policies
	1. Organization, Description of Business and Summary of Significant Accounting Policies
	Organization
	Corium International, Inc., a Delaware corporation (the “Company”), is a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage its broad experience in transdermal and transmucosal delivery systems.
	In the normal course of business, the Company enters into collaborative agreements with partners to develop and manufacture products based on the Company’s drug delivery technologies and product development expertise. Revenues consist of net sales of products manufactured, royalties and profit-sharing payments based on sales of such products by partners, and product development fees for research and development activities under collaborative agreements with strategic partners. The Company is also engaged in the research and development of its own transdermal drug delivery products using its proprietary technologies.
	The Company’s fiscal year ends on September 30.  References to “fiscal” refer to the years ended September 30.
	Basis of Presentation
	The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and follow the requirements of the Securities and Exchange Commission (the “SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The interim balance sheet as of March 31, 2015 and the statements of operations and comprehensive income (loss) for the three and six months ended March 31, 2015 and 2014, statement of stockholders’ equity (deficit) for the six months ended March 31, 2015 and statements of cash flows for the six months ended March 31, 2015 and 2014 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly the Company’s financial position as of March 31, 2015 and its results of operations for the three and six months ended March 31, 2015 and 2014 and cash flows for the six months ended March 31, 2015 and 2014. The financial data and the other financial information contained in these notes to the financial statements related to the three and six month periods are also unaudited. The results of operations for the six months ended March 31, 2015 are not necessarily indicative of the results to be expected for the year ending September 30, 2015 or for any future annual or interim period. The balance sheet as of September 30, 2014 has been derived from the audited financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.
	The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended September 30, 2014 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on December 15, 2014.
	There have been no material changes to the significant accounting policies previously disclosed in the Company’s audited financial statements for the year ended September 30, 2014.
	Initial Public Offering
	In April 2014, the Company sold 6,874,997 shares of its common stock in its initial public offering (the “IPO”) at a price of $8.00 per share.  The Company received net cash proceeds of $48.5 million from the IPO, including proceeds from the partial exercise of the underwriters’ option, after deducting underwriting discounts, commissions and issuance costs paid by the Company.
	On April 8, 2014, immediately prior to the closing of the IPO, all outstanding shares of convertible preferred stock were converted into 3,567,807 shares of common stock, and the related carrying value of $57.3 million was reclassified to common stock and additional paid-in capital. In addition, certain warrants to purchase convertible preferred stock and common stock were converted and net exercised into 971,440 shares of common stock. In connection with the IPO, Corium also repurchased 1,077,809 shares of common stock from its founders for an aggregate purchase price of $5.2 million.
	Following the filing of the Restated Certificate of Incorporation of the Company on April 8, 2014, the number of shares of capital stock the Company is authorized to issue is 155,000,000 shares, of which 150,000,000 shares may be common stock and 5,000,000 shares may be preferred stock. Both the common stock and preferred stock have a par value of $0.001 per share.
	Use of Estimates
	Estimates and assumptions are required to be used by management in the preparation of financial statements in conformity with U.S. GAAP that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of operating revenues and operating expenses during the reporting period. Those estimates and assumptions affect revenue recognition and deferred revenues, impairment of long-lived assets, determination of fair value of stock-based awards and other debt- and equity-related instruments, and accounting for income taxes. As future events and their effects cannot be determined with precision, actual results could differ from those estimates.
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents with a single domestic financial institution that is well capitalized. The Company provides credit, in the normal course of business, to its partners and performs credit evaluations of such partners.
	Four partners accounted for 89% of the Company’s revenues for both the three and six months ended March 31, 2015, compared to 92% and 94% for the corresponding periods in 2014. These same four partners accounted for 71% and 95% of accounts receivable as of March 31, 2015 and September 30, 2014, respectively.
	Comprehensive Income (Loss)
	During the three and six months ended March 31, 2015 and 2014, the Company did not recognize any other comprehensive income (loss) and, therefore, the net income (loss) and comprehensive income (loss) was the same for all periods presented.
	Revenue Recognition
	The Company generates revenues from agreements for the development and commercialization of its products. The terms of the agreements may include nonrefundable upfront payments, partial or complete reimbursement of research and development costs, milestone payments, product sales, and royalties and profit sharing on product sales derived from partner agreements. The Company recognizes revenues when the following criteria are met: persuasive evidence of a sales arrangement exists; delivery has occurred; the price is fixed or determinable; and collectability is reasonably assured.
	Revenue related to multiple element arrangements are analyzed to determine whether the deliverables can be separated or whether they must be accounted for as a single unit of accounting. This determination is generally based on whether any deliverable has stand-alone value to the partner. This analysis also establishes a selling price hierarchy for determining how to allocate arrangement consideration to identified units of accounting. The selling price used for each unit of accounting is based on vendor-specific objective evidence, if available, third-party evidence if vendor-specific objective evidence is not available, or estimated selling price if neither vendor-specific nor third-party evidence is available. Typically, the Company has not granted licenses to partners at the beginning of its arrangements and thus there are no delivered items separate from the research and development services provided. As such, upfront payments are recorded as deferred revenues in the balance sheet and are recognized as contract research and development revenues over the estimated period of performance that is consistent with the terms of the research and development obligations contained in the agreement. The Company periodically reviews the estimated period of performance based on the progress made under each arrangement.
	Amounts related to research and development funding are generally recognized as the related services or activities are performed, in accordance with the contract terms. To the extent that agreements specify services are to be performed on a cost-plus basis, revenues are recognized as services are rendered. Such work is generally billed on a monthly basis for time incurred at specified rates in the agreements. To the extent that agreements specify services to be performed on a fixed-price basis, revenues are recognized consistent with the pattern of the work performed. Generally, all of the agreements provide for reimbursement of third-party expenses, and such reimbursable expenses are billed as revenues at the time the associated expenses are incurred.
	The arrangements include contractual milestones, which relate to the achievement of pre-specified research, development, regulatory and commercialization events. The milestone events contained in the Company’s arrangements generally coincide with the progression of the Company’s product candidates through research and development, to regulatory approval, and through to commercialization. The process of successfully developing a new product, having it approved from a regulatory perspective, and ultimately sold for a profit, is highly uncertain. As such, the milestone payments that the Company earns from its partners involve a significant degree of risk to achieve. Research and development milestones in the Company’s strategic alliances includes the following types of events: completion of pre-clinical research and development work, completion of certain development events and initiation or completion of clinical trials. Regulatory milestones may include the following types of events: filing of regulatory applications with the Food and Drug Administration and approval of the regulatory applications by the Food and Drug Administration. Commercialization milestones generally relate to product launch. The Company recognizes milestone payments in their entirety in the period in which the milestone is achieved.
	Upon commercialization, revenues are generated from product sales, royalties and profit sharing. Product sales are generally recognized as products are shipped and title and risk of loss pass to the partner. Royalties and profit sharing are generally recognized when the partners sell the product to their customers, which could be in a different accounting period than the period in which we sold that product to our partners, and are based on a percentage of the partners’ gross sales or net profits of the products as specified in the underlying agreements. Royalties and profit sharing totaled $0.6 million and $1.2 million for the three and six months ended March 31, 2015, compared to $1.1 million and $3.0 million for the corresponding periods in 2014.
	Other revenues consists primarily of income derived from the Company’s arrangements with its partners, whereby a portion of the revenues received under these agreements relates to rental income from embedded leases associated with these relationships, as well as revenues associated with licenses granted to a third party for intellectual property related to thin film dressings.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Mar. 31, 2015
Fair Value Measurements
Fair Value Measurements
	2. Fair Value Measurements
	Financial assets and liabilities are recorded at fair value. Except as noted below, the carrying values of the Company’s financial instruments, including cash equivalents, accounts receivable, and accounts payable, approximated their fair values due to the short period of time to maturity or repayment.
	Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset, or an exit price that would be paid to transfer a liability, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:
	Level I —Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;
	Level II —Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and
	Level III —Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.
	The Company’s financial assets that are measured at fair value on a recurring basis by level within the fair value hierarchy are as follows (in thousands):
		As of March 31, 2015
		Level I		Level II		Level III		Total
	Financial Assets:
	Money market funds	$	33,593	$	—	$	—	$	33,593
	Total financial assets	$	33,593	$	—	$	—	$	33,593
		As of September 30, 2014
		Level I		Level II		Level III		Total
	Financial Assets:
	Money market funds	$	36,019	$	—	$	—	$	36,019
	Total financial assets	$	36,019	$	—	$	—	$	36,019
	The following financial liabilities have carrying values which differ from their fair value as estimated by the Company for instruments with similar terms and remaining maturities (Level III valuation technique) (in thousands):
		As of March 31, 2015
		Carrying		Fair		Difference
		Value		Value
	Long-term debt	$	49,024	$	49,145	$	121
	Total	$	49,024	$	49,145	$	121
		As of September 30, 2014
		Carrying		Fair		Difference
		Value		Value
	Long-term debt	$	38,262	$	40,357	$	2,095
	Total	$	38,262	$	40,357	$	2,095

Inventories

Inventories	6 Months Ended
	Mar. 31, 2015
Inventories
Inventories
	3. Inventories
	Inventories consist of the following (in thousands):
		As of			As of
		March 31,			September 30,
		2015			2014
	Raw materials	$	1,700		$	1,268
	Work in process	850			898
	Finished goods	564			632
	Total inventories, cost	3,114			2,798
	Less inventory reserves	(153		)	(206		)
	Total inventories, net	$	2,961		$	2,592

LongTerm_Debt

Long-Term Debt	6 Months Ended
	Mar. 31, 2015
Long-Term Debt
Long-Term Debt
	4. Long-Term Debt
	The Company’s outstanding long-term debt was as follows (in thousands):
		As of March		As of
		31, 2015		September
				30, 2014
	Term loan agreement expiring June 30, 2019, less discount of $66 and $76 as of March 31, 2015 and September 30, 2014, respectively. See terms of the agreement below.	$	48,421	$	37,625
	Notes payable to lessor for tenant improvements. The note calls for monthly payments of principal and interest of $3 at an interest rate of 7% and is due April 2017	81		96
	Notes payable to lessor for tenant improvements. The note calls for monthly payments of principal and interest of $6 at an interest rate of 7% and is due November 2024	522		541
	Total	49,024		38,262
	Less current portion	54		107
	Long-term portion	$	48,970	$	38,155
	On July 13, 2012, the Company completed a $35.0 million term loan agreement with Capital Royalty Group, subsequently renamed as CRG (“CRG”), a healthcare-focused investment firm. In August 2012 and December 2012, the Company drew down $29.0 million and $6.0 million under this agreement, respectively, completing the principal borrowing authorized under that agreement. On November 14, 2014, the agreement was amended to, among other things, increase the principal amount of the term loan by $10.0 million, extend the interest-only period to June 30, 2018, and extend its maturity from June 30, 2017 to June 30, 2019. The amended agreement provides for a maximum borrowing of $45.0 million, excluding PIK notes, as defined below. The amended agreement requires interest to be paid quarterly at a simple annual rate of 15%, and all outstanding principal be repaid in four equal quarterly payments beginning on June 30, 2018, with interest continuing to accrue on the unpaid principal at a simple annual rate of 15%. In addition, the amended agreement contains a provision whereby the Company can, at each quarterly payment due date prior to June 30, 2018, choose to convert that portion of each quarterly interest obligation equal to 3.5% of the then-outstanding principal into additional notes. As of March 31, 2015 and September 30, 2014, the Company had converted $3.5 million and $2.7 million, respectively, of interest into such additional notes (also known as payment-in-kind (“PIK”) notes), each of which add to the outstanding principal.
	On December 4, 2014, the Company borrowed the remaining $10.0 million of principal provided for in the amended agreement. As of March 31, 2015, the principal amount outstanding under the term loan agreement, including all PIK notes, was $48.5 million. Amounts outstanding under the term loan agreement are collateralized by all of the Company’s assets. The amended agreement provides for a prepayment penalty on the outstanding principal if the Company chooses to repay principal prior to June 30, 2018, or upon other specified events, including a change of control. The term loan agreement provides for financial covenants for minimum annual revenues (beginning with the 12 months ending June 30, 2015) and minimum liquidity, with which the Company has been in continuous compliance since the inception of the loan.

Collaboration_and_Partner_Arra

Collaboration and Partner Arrangements	6 Months Ended
	Mar. 31, 2015
Collaboration and Partner Arrangements.
Collaboration and Partner Arrangements
	5. Collaboration and Partner Arrangements
	The Company has recognized the following revenues from its collaboration and partner agreements (in thousands):
		Three Months Ended March 31,				Six Months Ended March 31,
		2015		2014		2015		2014
	P&G	$	2,539	$	2,811	$	6,216	$	5,762
	Teva	3,922		2,784		5,826		6,487
	Par	2,611		3,405		4,863		6,528
	Agile	980		851		1,867		1,217
	Other	1,239		866		2,285		1,191
	Total revenues	$	11,291	$	10,717	$	21,057	$	21,185

Warrants

Warrants	6 Months Ended
	Mar. 31, 2015
Warrants
Warrants
	6. Warrants
	The Company issued warrants to purchase shares of the Company’s capital stock as part of several transactions from fiscal 2008 through fiscal 2013. The warrants had been recorded as either equity instruments or liability instruments at the date of their issuances based on the terms of the warrants.
	As of March 31, 2015, warrants to purchase 128,582 shares of common stock were outstanding with a weighted-average exercise price of $1.77 per share.  All of the common stock warrants are exercisable at any time up to five years from issuance.  The fair value of these warrants was recorded in stockholders’ equity upon issuance.

Convertible_Preferred_Stock_Co

Convertible Preferred Stock, Common Stock and Stockholders' Equity (Deficit)	6 Months Ended
	Mar. 31, 2015
Convertible Preferred Stock, Common Stock and Stockholders' Equity (Deficit)
Convertible Preferred Stock, Common Stock and Stockholders' Equity (Deficit)
	7. Convertible Preferred Stock, Common Stock and Stockholders’ Equity (Deficit)
	Convertible Preferred Stock
	The Company was authorized to issue up to 5.0 million shares of preferred stock as of March 31, 2015 and September 30, 2014 with a par value of $0.001 per share.  No preferred stock was outstanding as of that date.
	Common Stock
	The Company was authorized to issue up to 150.0 million shares of common stock as of March 31, 2015 and September 30, 2014 with a par value of $0.001 per share. As of March 31, 2015, there were 18,072,866 shares of common stock outstanding.

StockBased_Compensation

Stock-Based Compensation	6 Months Ended
	Mar. 31, 2015
Stock-Based Compensation
Stock-Based Compensation
	8. Stock-Based Compensation
	Equity Incentive Plans
	As of March 31, 2015 and September 30, 2014, the Company had four equity incentive plans, all of which are sponsored by the Company, with the exception of the separate stock option plan of StrataGent, Inc., a corporation acquired by the Company on September 20, 2007 (the “StrataGent Plan”). The Company assumed all unexpired, unexercised options outstanding for those employees of StrataGent who remained Company employees after the merger. Each StrataGent option became exercisable into whole shares of Corium stock based on an agreed exchange ratio and per share exercise price such that the total value of the option grant did not change. The Company elected to make no further grants under the StrataGent Plan, however, its terms continue to govern all options issued under that plan. No additional shares available for grant under the StrataGent Plan were assumed by the Company, and any options that were returned to the pool subsequent to the merger with StrataGent were canceled and were not made available for future grants. This wholly-owned subsidiary was dissolved in 2008. As of March 31, 2015, all StrataGent options had been either exercised or canceled.
	On March 20, 2014, the Company’s board of directors approved the adoption of the 2014 Equity Incentive Plan (the “2014 Plan”), which became effective in connection with the IPO. Under the 2014 Plan, the Company initially had reserved a total of 1.0 million shares of common stock plus the remaining unissued shares under the Company’s 2012 Equity Incentive Plan (the “2012 Plan”), which was adopted in November 2012 and was replaced by the 2014 Plan. The Company also sponsored the 2002 Stock Option Plan that expired in 2012. On January 1 of each year during the ten-year term of the 2014 Plan, the number of shares of common stock issuable under the 2014 Plan can be increased by an amount equal to up to 4% of the number of shares of common stock outstanding as of the preceding December 31, or such lesser number agreed to by the Company’s board of directors. On January 16, 2015, the Company’s board of directors authorized an increase of 722,834 shares to be added to the total number of shares of common stock issuable under the 2014 Plan.
	The exercise price of each option issued under each of the equity incentive plans is required to be no less than the fair value of the Company’s common stock, as determined by the Company’s board of directors on the date of the grant. The maximum term of the options is ten years and the vesting period is typically four years. The term “Corium Plans” refers to the 2014 Plan, the 2012 Plan and the 2002 Stock Option Plan.
	A summary of activity under the Corium Plans during the six months ended March 31, 2015 is as follows:
		Shares		Stock		Weighted			Weighted-	Aggregate
		Available		Options		Average			Average	Intrinsic
		for Grant		Outstanding		Exercise			Remaining	Value
						Price			Contractual
									Life
									(Years)
										(In
										thousands)
	Balance — September 30, 2014	949,885		2,085,028		$	2.92		7.02	$	6,710
	Additional shares authorized	722,834		—		—
	Granted	(689,950	)	689,950		$	5.57
	Exercised	—		(3,383	)	$	1.65
	Forfeited / Cancelled	3,785		(3,785	)	$	3.5
	Balance — March 31, 2015	986,554		2,767,810		$	3.58		7.28	$	8,219
	Options exercisable — March 31, 2015			1,458,272		$	2.67		5.81	$	5,658
	Options vested and expected to vest — March 31, 2015			2,647,448		$	3.51		4.23	$	8,048
	All outstanding options under the Corium Plans as of March 31, 2015 have an exercise price between $2.12 and $8.18 per share.
	The weighted-average fair value of the stock options granted for the six months ended March 31, 2015 were estimated using the Black-Scholes option-pricing model with the following assumptions:
		Six Months Ended
		March 31, 2015
	Expected term (in years)	5.27 – 6.63
	Expected volatility	70 – 77%
	Risk-free interest rate	1.6 – 1.9%
	Expected dividend rate	0%
	Expected Term — The expected term represents the period that the stock-based awards are expected to be outstanding before exercise or cancellation. As the Company’s historical share exercise experience has not yet provided a reasonable basis upon which to estimate expected term because of a lack of sufficient data points, the Company estimated the expected term by using the simplified method.
	Expected Volatility —Because the Company has limited information on the volatility of its common stock due to a lack of significant trading history and limited historical data regarding the volatility of its common stock, the expected volatility used is based on the volatility of a group of comparable publicly traded companies. In evaluating comparability, the Company considered factors such as industry, stage of life cycle and size. The Company will continue to analyze the historical stock price volatility and term assumptions as more historical data for the Company’s common stock becomes available.
	Risk-Free Interest Rate —The risk-free interest rate is based on the constant maturity yields of U.S. Treasury notes with remaining maturities similar to the expected term.
	Expected Dividend Rate —The Company has never paid any dividends, does not plan to pay dividends in the foreseeable future, and, therefore, uses an expected dividend rate of zero in the valuation model.
	2014 Employee Stock Purchase Plan
	On March 20, 2014, the Company’s board of directors approved the adoption of the 2014 Employee Stock Purchase Plan (the “2014 ESPP”), which became effective in connection with the IPO. On January 1 of each year during the ten-year term of the plan, the number of shares issuable under the 2014 ESPP can be increased by an amount equal to up to 1% of the number of shares of common stock and common stock equivalents outstanding as of the preceding December 31, or a lesser number agreed to by the board of directors. No more than 4.0 million shares may be issued over the ten-year term of the 2014 ESPP without the consent of the Company’s stockholders. Shares subject to purchase rights granted under the Company’s 2014 ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the Company’s 2014 ESPP.
	The Company initially had reserved 310,000 shares of common stock for issuance pursuant to the 2014 ESPP upon its adoption and, on January 16, 2015, the Company’s board of directors reserved an additional 181,994 shares of common stock for issuance pursuant to the 2014 ESPP. As of March 31, 2015, the total reserve available for issuance pursuant to the 2014 ESPP was 430,952 shares of common stock, which reserve is net of issuances of 61,042 shares of common stock. The 2014 ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code of 1986 with the purpose of providing employees with an opportunity to purchase the Company’s common stock through accumulated payroll deductions.
	The 2014 ESPP provides for a 24-month offering period with four consecutive six-month purchase periods during each offering period. Employees are able to purchase shares of common stock at 85% of the lower of the fair market value of the Company’s common stock on the first day of the offering period (the “Offering Date”) or on the last day of each six-month purchase period (the “Purchase Date”). The closing price as quoted by the Nasdaq is deemed to be the fair value of the Company’s common stock on the Offering Date or the Purchase Date, or if there are no sales on such date, then the last preceding business day on which there were sales.  In the event that the closing price of the Company’s common stock on the Purchase Date is lower than it was on the Offering Date, then all participating employees may re-enroll in a new 24-month offering period that commences the day following the Purchase Date.
	The first Purchase Date of the April 2, 2014 offering period of the Company’s 2014 ESPP was November 19, 2014.  The closing price of the Company’s common stock on that date was $5.73, which was lower than the $8.00 fair market value on the Offering Date.  Accordingly, all participants who acquired shares on the first Purchase Date received a purchase price equal to 85% of $5.73, or $4.87.
	The fair value of the purchase rights granted under the 2014 ESPP between April 2, 2014 and November 19, 2014 and the offering period commencing on November 20, 2014 were estimated by applying the Black-Scholes option-pricing model to each of the four purchase periods in each offering period using the following assumptions:
		Six Months Ended
		March 31, 2015
	Fair value of common stock	$5.73 – 8.00
	Grant price	$4.87 – 6.80
	Expected term (in years)	0.50 – 2.00
	Expected volatility	47 – 51%
	Risk-free interest rate	0.07 – 0.54%
	Expected dividend rate	0%
	Fair Value of Common Stock —The fair market value of the Company’s common stock on the first day of each offering period, or $8.00 for the first offering period, based on the Company’s IPO price, and $5.73 for the new offering period commencing on November 20, 2014.
	Grant Price —85% of the fair market value of the Company’s common stock on the first day of each offering period, or $6.80 for the first offering period and $4.87 for the new offering period commencing November 20, 2014.
	Expected Terms —The expected terms are based on the end dates of the four purchase periods of each ESPP offering period, which are six, twelve, eighteen and twenty four months from the commencement of each new offering period.
	Expected Volatility —Because the Company has limited information on the volatility of its common stock due to a lack of significant trading history and limited historical data regarding the volatility of its common stock, the expected volatility used is based on the volatility of a group of comparable publicly traded companies. In evaluating comparability, the Company considered factors such as industry, stage of life cycle and size. The Company will continue to analyze the historical stock price volatility and term assumptions as more historical data for the Company’s common stock becomes available.
	Risk-Free Interest Rate —The risk-free interest rate is based on the constant maturity yields of U.S. Treasury notes with remaining maturities similar to each expected term.
	Expected Dividend Rate —The Company has never paid any dividends, does not plan to pay dividends in the foreseeable future, and, therefore, uses an expected dividend rate of zero in the valuation model.
	For the three and six months ended March 31, 2015, the Company recorded stock-based compensation expense of $111,000 and $275,000, respectively, and for the six months ended March 31, 2015 issued 61,042 shares of common stock to employees related to the 2014 ESPP.
	Stock-Based Compensation Expense
	Employee stock-based compensation expense for the three and six months ended March 31, 2015 and 2014 is classified in the condensed statements of operations and comprehensive income (loss) as follows (in thousands):
		Three Months Ended March 31,						Six Months Ended March 31,
		2015			2014			2015		2014
	Cost of product revenues	$	82		$	5		$	185	$	11
	Cost of contract research and development revenues	46			5			103		9
	Research and development	143			16			268		23
	General and administrative	405			168			808		207
Total stock-based compensation	$	676		$	194		$	1,364	$	250
As of March 31, 2015, there was a total of $5.2 million of unrecognized employee stock-based compensation expense, net of estimated forfeitures, related to unvested stock option awards, which is expected to be recognized on a straight-line basis over a weighted-average period of approximately 2.9 years.

Product_Recall_Liability

Product Recall Liability	6 Months Ended
	Mar. 31, 2015
Product Recall Liability
Product Recall Liability
	9. Product Recall Liability
	In fiscal 2008 and fiscal 2010, Actavis issued two voluntary recalls of certain lots and strengths of Fentanyl TDS manufactured by the Company and sold and distributed by Actavis in the United States. The Company and Actavis negotiated financial settlements for these two recalls, and the Company accrued amounts related to these settlements in fiscal 2009 and 2011. These recall liabilities were subsequently reduced through various mechanisms per the terms of the settlement agreements.
	In October 2012, the Company reached a revised settlement related to the two recalls, which provided for a total and combined remaining liability of $5.0 million as of that date. The revised liability will be repaid through quarterly payments in arrears based on a percentage of the average of the total net revenues recorded by the Company related to Fentanyl TDS. These quarterly payments have been paid to Actavis since July 1, 2013 and will continue through April 1, 2017. To the extent that the revised settlement liability has not been fully repaid as of April 1, 2017, the remaining liability, if any, will be converted into the most recent form of capital stock issued by the Company in connection with a financing, at the price per share of that financing. The revised liability does not accrue interest.
	The following table summarizes the changes to the product recall liability (in thousands):
		Six months
		ended
		March 31, 2015
	Balance at September 30, 2014	$	3,710
	Payment of settlement liability	(359		)
	Balance at March 31, 2015	$	3,351

Net_Income_Loss_and_Net_Income

Net Income (Loss) and Net Income (Loss) per Share Attributable to Common Stockholders	6 Months Ended
	Mar. 31, 2015
Net Income (Loss) and Net Income (Loss) per Share Attributable to Common Stockholders
Net Income (Loss) and Net Income (Loss) per Share Attributable to Common Stockholders
	10. Net Income (Loss) and Net Income (Loss) per Share Attributable to Common Stockholders
	In April 2014, the Company completed its IPO, which resulted in significant changes to the number of then-outstanding shares of common stock. The following table sets forth the computation of the Company’s basic and diluted net income (loss) per share attributable to common stockholders during the three and six months ended March 31, 2015 and 2014 (in thousands, except share and per share data):
		Three Months Ended						Six Months Ended
		March 31,						March 31,
		2015			2014			2015			2014
	Basic Net income (loss) per share
	Net income (loss) attributable to common stockholders, basic and diluted	$	(7,142	)	$	3,534		$	(13,901	)	$	1,436
	Less: undistributed earnings attributable to participating securities	—			(2,420		)	—			(1,375		)
	Net income (loss) attributable to common stockholders, basic	$	(7,142	)	$	1,114		$	(13,901	)	$	61
	Weighted-average shares used in computing net income (loss) per share attributable to common stockholders, basic	18,071,320			2,232,300			18,052,809			2,231,049
	Net income (loss) attributable to common stockholders, basic	$	(0.40	)	$	0.5		$	(0.77	)	$	0.03
		Three Months Ended						Six Months Ended
		March 31,						March 31,
		2015			2014			2015			2014
	Fully Diluted Net income (loss) per share
	Net income (loss) attributable to common stockholders, basic and diluted	$	(7,142	)	$	3,534		$	(13,901	)	$	1,436
	Less: undistributed earnings attributable to participating securities	—			(1,573		)	—			(1,358		)
	Net income (loss) attributable to common stockholders, diluted	$	(7,142	)	$	1,961		$	(13,901	)	$	78
	Weighted-average shares used in computing net income (loss) per share attributable to common stockholders, basic	18,071,320			2,232,300			18,052,809			2,231,049
	Effect of potentially dilutive securities:	—			—			—			—
	Dilutive options	—			756,300			—			518,655
	Assumed conversion of convertible notes	—			2,063,989			—			—
	Common stock warrants	—			877,720			—			733,252
	Weighted-average shares used in computing net income (loss) per share attributable to common stockholders, diluted	18,071,320			5,930,309			18,052,809			3,482,956
	Net income (loss) attributable to common stockholders, diluted	$	(0.40	)	$	0.33		$	(0.77	)	$	0.02
	The following outstanding shares of common stock equivalents were excluded from the computation of the diluted net income (loss) per share attributable to common stockholders for the periods presented because including them would have been antidilutive:
		Three months ended				Six months ended
		March 31,				March 31,
		2015		2014		2015		2014
	Convertible preferred stock	—		3,567,807		—		3,537,807
	Stock options to purchase common stock	2,767,810		—		2,767,810		37,902
	Shares authorized under the 2014 ESPP	430,952		—		430,952		—
	Common stock warrants	128,582		—		128,582		—
	Preferred stock warrants	—		170,962		—		136,658
	Convertible notes	—		—		—		2,090,604

Income_Taxes

Income Taxes	6 Months Ended
	Mar. 31, 2015
Income Taxes
Income Taxes
	11. Income Taxes
	The Company did not record a provision for Federal income taxes for the three and six months ended March 31, 2015 because it expected to generate a net operating loss for the year ending September 31, 2015.  The income tax expense of $2,000 for the six months ended March 31, 2015 represents minimum statutory payments due in the states in which the Company is subject to taxation.  The Company’s deferred tax assets continue to be fully offset by a valuation allowance.

Segment_and_EnterpriseWide_Inf

Segment and Enterprise-Wide Information	6 Months Ended
	Mar. 31, 2015
Segment and Enterprise-Wide Information
Segment and Enterprise-Wide Information
	12. Segment and Enterprise-Wide Information
	The Company’s chief operating decision maker is its President and Chief Executive Officer. The President and Chief Executive Officer reviews the Company’s operating results on an aggregate basis for purposes of allocating resources and evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations or operating results for levels or components. Accordingly, the Company has a single reporting segment and operating unit structure.
	All of the Company’s revenues are derived from partners located in the United States and all long-lived assets are located in the United States.

Organization_Description_of_Bu1

Organization, Description of Business, and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Mar. 31, 2015
Organization, Description of Business, and Summary of Significant Accounting Policies
Organization
	Organization
	Corium International, Inc., a Delaware corporation (the “Company”), is a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage its broad experience in transdermal and transmucosal delivery systems.
	In the normal course of business, the Company enters into collaborative agreements with partners to develop and manufacture products based on the Company’s drug delivery technologies and product development expertise. Revenues consist of net sales of products manufactured, royalties and profit-sharing payments based on sales of such products by partners, and product development fees for research and development activities under collaborative agreements with strategic partners. The Company is also engaged in the research and development of its own transdermal drug delivery products using its proprietary technologies.
	The Company’s fiscal year ends on September 30.  References to “fiscal” refer to the years ended September 30.
Basis of Presentation
	Basis of Presentation
	The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and follow the requirements of the Securities and Exchange Commission (the “SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The interim balance sheet as of March 31, 2015 and the statements of operations and comprehensive income (loss) for the three and six months ended March 31, 2015 and 2014, statement of stockholders’ equity (deficit) for the six months ended March 31, 2015 and statements of cash flows for the six months ended March 31, 2015 and 2014 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly the Company’s financial position as of March 31, 2015 and its results of operations for the three and six months ended March 31, 2015 and 2014 and cash flows for the six months ended March 31, 2015 and 2014. The financial data and the other financial information contained in these notes to the financial statements related to the three and six month periods are also unaudited. The results of operations for the six months ended March 31, 2015 are not necessarily indicative of the results to be expected for the year ending September 30, 2015 or for any future annual or interim period. The balance sheet as of September 30, 2014 has been derived from the audited financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.
	The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended September 30, 2014 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on December 15, 2014.
	There have been no material changes to the significant accounting policies previously disclosed in the Company’s audited financial statements for the year ended September 30, 2014.
Initial Public Offering
	Initial Public Offering
	In April 2014, the Company sold 6,874,997 shares of its common stock in its initial public offering (the “IPO”) at a price of $8.00 per share.  The Company received net cash proceeds of $48.5 million from the IPO, including proceeds from the partial exercise of the underwriters’ option, after deducting underwriting discounts, commissions and issuance costs paid by the Company.
	On April 8, 2014, immediately prior to the closing of the IPO, all outstanding shares of convertible preferred stock were converted into 3,567,807 shares of common stock, and the related carrying value of $57.3 million was reclassified to common stock and additional paid-in capital. In addition, certain warrants to purchase convertible preferred stock and common stock were converted and net exercised into 971,440 shares of common stock. In connection with the IPO, Corium also repurchased 1,077,809 shares of common stock from its founders for an aggregate purchase price of $5.2 million.
	Following the filing of the Restated Certificate of Incorporation of the Company on April 8, 2014, the number of shares of capital stock the Company is authorized to issue is 155,000,000 shares, of which 150,000,000 shares may be common stock and 5,000,000 shares may be preferred stock. Both the common stock and preferred stock have a par value of $0.001 per share.
Use of Estimates
	Use of Estimates
	Estimates and assumptions are required to be used by management in the preparation of financial statements in conformity with U.S. GAAP that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of operating revenues and operating expenses during the reporting period. Those estimates and assumptions affect revenue recognition and deferred revenues, impairment of long-lived assets, determination of fair value of stock-based awards and other debt- and equity-related instruments, and accounting for income taxes. As future events and their effects cannot be determined with precision, actual results could differ from those estimates.
Concentration of Credit Risk
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents with a single domestic financial institution that is well capitalized. The Company provides credit, in the normal course of business, to its partners and performs credit evaluations of such partners.
	Four partners accounted for 89% of the Company’s revenues for both the three and six months ended March 31, 2015, compared to 92% and 94% for the corresponding periods in 2014. These same four partners accounted for 71% and 95% of accounts receivable as of March 31, 2015 and September 30, 2014, respectively.
Comprehensive Income (Loss)
	Comprehensive Income (Loss)
	During the three and six months ended March 31, 2015 and 2014, the Company did not recognize any other comprehensive income (loss) and, therefore, the net income (loss) and comprehensive income (loss) was the same for all periods presented.
Revenue Recognition
	Revenue Recognition
	The Company generates revenues from agreements for the development and commercialization of its products. The terms of the agreements may include nonrefundable upfront payments, partial or complete reimbursement of research and development costs, milestone payments, product sales, and royalties and profit sharing on product sales derived from partner agreements. The Company recognizes revenues when the following criteria are met: persuasive evidence of a sales arrangement exists; delivery has occurred; the price is fixed or determinable; and collectability is reasonably assured.
	Revenue related to multiple element arrangements are analyzed to determine whether the deliverables can be separated or whether they must be accounted for as a single unit of accounting. This determination is generally based on whether any deliverable has stand-alone value to the partner. This analysis also establishes a selling price hierarchy for determining how to allocate arrangement consideration to identified units of accounting. The selling price used for each unit of accounting is based on vendor-specific objective evidence, if available, third-party evidence if vendor-specific objective evidence is not available, or estimated selling price if neither vendor-specific nor third-party evidence is available. Typically, the Company has not granted licenses to partners at the beginning of its arrangements and thus there are no delivered items separate from the research and development services provided. As such, upfront payments are recorded as deferred revenues in the balance sheet and are recognized as contract research and development revenues over the estimated period of performance that is consistent with the terms of the research and development obligations contained in the agreement. The Company periodically reviews the estimated period of performance based on the progress made under each arrangement.
	Amounts related to research and development funding are generally recognized as the related services or activities are performed, in accordance with the contract terms. To the extent that agreements specify services are to be performed on a cost-plus basis, revenues are recognized as services are rendered. Such work is generally billed on a monthly basis for time incurred at specified rates in the agreements. To the extent that agreements specify services to be performed on a fixed-price basis, revenues are recognized consistent with the pattern of the work performed. Generally, all of the agreements provide for reimbursement of third-party expenses, and such reimbursable expenses are billed as revenues at the time the associated expenses are incurred.
	The arrangements include contractual milestones, which relate to the achievement of pre-specified research, development, regulatory and commercialization events. The milestone events contained in the Company’s arrangements generally coincide with the progression of the Company’s product candidates through research and development, to regulatory approval, and through to commercialization. The process of successfully developing a new product, having it approved from a regulatory perspective, and ultimately sold for a profit, is highly uncertain. As such, the milestone payments that the Company earns from its partners involve a significant degree of risk to achieve. Research and development milestones in the Company’s strategic alliances includes the following types of events: completion of pre-clinical research and development work, completion of certain development events and initiation or completion of clinical trials. Regulatory milestones may include the following types of events: filing of regulatory applications with the Food and Drug Administration and approval of the regulatory applications by the Food and Drug Administration. Commercialization milestones generally relate to product launch. The Company recognizes milestone payments in their entirety in the period in which the milestone is achieved.
	Upon commercialization, revenues are generated from product sales, royalties and profit sharing. Product sales are generally recognized as products are shipped and title and risk of loss pass to the partner. Royalties and profit sharing are generally recognized when the partners sell the product to their customers, which could be in a different accounting period than the period in which we sold that product to our partners, and are based on a percentage of the partners’ gross sales or net profits of the products as specified in the underlying agreements. Royalties and profit sharing totaled $0.6 million and $1.2 million for the three and six months ended March 31, 2015, compared to $1.1 million and $3.0 million for the corresponding periods in 2014.
	Other revenues consists primarily of income derived from the Company’s arrangements with its partners, whereby a portion of the revenues received under these agreements relates to rental income from embedded leases associated with these relationships, as well as revenues associated with licenses granted to a third party for intellectual property related to thin film dressings.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Mar. 31, 2015
Fair Value Measurements
Schedule of the Company's financial assets that are measured at fair value on a recurring basis by level within the fair value hierarchy
	The Company’s financial assets that are measured at fair value on a recurring basis by level within the fair value hierarchy are as follows (in thousands):
		As of March 31, 2015
		Level I		Level II		Level III		Total
	Financial Assets:
	Money market funds	$	33,593	$	—	$	—	$	33,593
	Total financial assets	$	33,593	$	—	$	—	$	33,593
		As of September 30, 2014
		Level I		Level II		Level III		Total
	Financial Assets:
	Money market funds	$	36,019	$	—	$	—	$	36,019
	Total financial assets	$	36,019	$	—	$	—	$	36,019
Schedule of differences between carrying values and estimated fair value of financial instruments
	The following financial liabilities have carrying values which differ from their fair value as estimated by the Company for instruments with similar terms and remaining maturities (Level III valuation technique) (in thousands):
		As of March 31, 2015
		Carrying		Fair		Difference
		Value		Value
	Long-term debt	$	49,024	$	49,145	$	121
	Total	$	49,024	$	49,145	$	121
		As of September 30, 2014
		Carrying		Fair		Difference
		Value		Value
	Long-term debt	$	38,262	$	40,357	$	2,095
	Total	$	38,262	$	40,357	$	2,095

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Mar. 31, 2015
Inventories
Schedule of Inventories
	Inventories consist of the following (in thousands):
		As of			As of
		March 31,			September 30,
		2015			2014
	Raw materials	$	1,700		$	1,268
	Work in process	850			898
	Finished goods	564			632
	Total inventories, cost	3,114			2,798
	Less inventory reserves	(153		)	(206		)
	Total inventories, net	$	2,961		$	2,592

LongTerm_Debt_Tables

Long-Term Debt (Tables)	6 Months Ended
	Mar. 31, 2015
Long-Term Debt
Schedule of the entity's outstanding debt
	The Company’s outstanding long-term debt was as follows (in thousands):
		As of March		As of
		31, 2015		September
				30, 2014
	Term loan agreement expiring June 30, 2019, less discount of $66 and $76 as of March 31, 2015 and September 30, 2014, respectively. See terms of the agreement below.	$	48,421	$	37,625
	Notes payable to lessor for tenant improvements. The note calls for monthly payments of principal and interest of $3 at an interest rate of 7% and is due April 2017	81		96
	Notes payable to lessor for tenant improvements. The note calls for monthly payments of principal and interest of $6 at an interest rate of 7% and is due November 2024	522		541
	Total	49,024		38,262
	Less current portion	54		107
	Long-term portion	$	48,970	$	38,155

Collaboration_and_Partner_Arra1

Collaboration and Partner Arrangements (Tables)	6 Months Ended
	Mar. 31, 2015
Collaboration and Partner Arrangements.
Schedule of revenues from the entity's collaboration and partner agreements
	The Company has recognized the following revenues from its collaboration and partner agreements (in thousands):
		Three Months Ended March 31,				Six Months Ended March 31,
		2015		2014		2015		2014
	P&G	$	2,539	$	2,811	$	6,216	$	5,762
	Teva	3,922		2,784		5,826		6,487
	Par	2,611		3,405		4,863		6,528
	Agile	980		851		1,867		1,217
	Other	1,239		866		2,285		1,191
	Total revenues	$	11,291	$	10,717	$	21,057	$	21,185

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	6 Months Ended
	Mar. 31, 2015
Stock-based compensation
Schedule of employee stock-based compensation expense classified in the statements of operations and comprehensive income (loss)
	Employee stock-based compensation expense for the three and six months ended March 31, 2015 and 2014 is classified in the condensed statements of operations and comprehensive income (loss) as follows (in thousands):
		Three Months Ended March 31,						Six Months Ended March 31,
		2015			2014			2015		2014
	Cost of product revenues	$	82		$	5		$	185	$	11
	Cost of contract research and development revenues	46			5			103		9
	Research and development	143			16			268		23
	General and administrative	405			168			808		207
	Total stock-based compensation	$	676		$	194		$	1,364	$	250
Corium Plans
Stock-based compensation
Summary of activity under the Plans
		Shares		Stock		Weighted			Weighted-	Aggregate
		Available		Options		Average			Average	Intrinsic
		for Grant		Outstanding		Exercise			Remaining	Value
						Price			Contractual
									Life
									(Years)
										(In
										thousands)
	Balance — September 30, 2014	949,885		2,085,028		$	2.92		7.02	$	6,710
	Additional shares authorized	722,834		—		—
	Granted	(689,950	)	689,950		$	5.57
	Exercised	—		(3,383	)	$	1.65
	Forfeited / Cancelled	3,785		(3,785	)	$	3.5
	Balance — March 31, 2015	986,554		2,767,810		$	3.58		7.28	$	8,219
	Options exercisable — March 31, 2015			1,458,272		$	2.67		5.81	$	5,658
	Options vested and expected to vest — March 31, 2015			2,647,448		$	3.51		4.23	$	8,048
Schedule of valuation assumptions used
		Six Months Ended
		March 31, 2015
	Expected term (in years)	5.27 – 6.63
	Expected volatility	70 – 77%
	Risk-free interest rate	1.6 – 1.9%
	Expected dividend rate	0%
2014 Employee Stock Purchase Plan
Stock-based compensation
Schedule of valuation assumptions used
		Six Months Ended
		March 31, 2015
	Fair value of common stock	$5.73 – 8.00
	Grant price	$4.87 – 6.80
	Expected term (in years)	0.50 – 2.00
	Expected volatility	47 – 51%
	Risk-free interest rate	0.07 – 0.54%
	Expected dividend rate	0%

Product_Recall_Liability_Table

Product Recall Liability (Tables)	6 Months Ended
	Mar. 31, 2015
Product Recall Liability
Summary of changes to the product recall liability
	The following table summarizes the changes to the product recall liability (in thousands):
		Six months
		ended
		March 31, 2015
	Balance at September 30, 2014	$	3,710
	Payment of settlement liability	(359		)
	Balance at March 31, 2015	$	3,351

Net_Income_Loss_and_Net_Income1

Net Income (Loss) and Net Income (Loss) per Share Attributable to Common Stockholders (Tables)	6 Months Ended
	Mar. 31, 2015
Net Income (Loss) and Net Income (Loss) per Share Attributable to Common Stockholders
Schedule of computation of the Company's basic and diluted net income (loss) per share attributable to common stockholders	The following table sets forth the computation of the Company’s basic and diluted net income (loss) per share attributable to common stockholders during the three and six months ended March 31, 2015 and 2014 (in thousands, except share and per share data):
		Three Months Ended						Six Months Ended
		March 31,						March 31,
		2015			2014			2015			2014
	Basic Net income (loss) per share
	Net income (loss) attributable to common stockholders, basic and diluted	$	(7,142	)	$	3,534		$	(13,901	)	$	1,436
	Less: undistributed earnings attributable to participating securities	—			(2,420		)	—			(1,375		)
	Net income (loss) attributable to common stockholders, basic	$	(7,142	)	$	1,114		$	(13,901	)	$	61
	Weighted-average shares used in computing net income (loss) per share attributable to common stockholders, basic	18,071,320			2,232,300			18,052,809			2,231,049
	Net income (loss) attributable to common stockholders, basic	$	(0.40	)	$	0.5		$	(0.77	)	$	0.03
		Three Months Ended						Six Months Ended
		March 31,						March 31,
		2015			2014			2015			2014
	Fully Diluted Net income (loss) per share
	Net income (loss) attributable to common stockholders, basic and diluted	$	(7,142	)	$	3,534		$	(13,901	)	$	1,436
	Less: undistributed earnings attributable to participating securities	—			(1,573		)	—			(1,358		)
	Net income (loss) attributable to common stockholders, diluted	$	(7,142	)	$	1,961		$	(13,901	)	$	78
	Weighted-average shares used in computing net income (loss) per share attributable to common stockholders, basic	18,071,320			2,232,300			18,052,809			2,231,049
	Effect of potentially dilutive securities:	—			—			—			—
	Dilutive options	—			756,300			—			518,655
	Assumed conversion of convertible notes	—			2,063,989			—			—
	Common stock warrants	—			877,720			—			733,252
	Weighted-average shares used in computing net income (loss) per share attributable to common stockholders, diluted	18,071,320			5,930,309			18,052,809			3,482,956
	Net income (loss) attributable to common stockholders, diluted	$	(0.40	)	$	0.33		$	(0.77	)	$	0.02
Schedule of anti-dilutive securities excluded from calculation of diluted net income (loss) per share attributable to common stockholders
		Three months ended				Six months ended
		March 31,				March 31,
		2015		2014		2015		2014
	Convertible preferred stock	—		3,567,807		—		3,537,807
	Stock options to purchase common stock	2,767,810		—		2,767,810		37,902
	Shares authorized under the 2014 ESPP	430,952		—		430,952		—
	Common stock warrants	128,582		—		128,582		—
	Preferred stock warrants	—		170,962		—		136,658
	Convertible notes	—		—		—		2,090,604

Organization_Description_of_Bu2

Organization, Description of Business, and Summary of Significant Accounting Policies (Details) (USD $)	0 Months Ended	1 Months Ended
In Millions, except Share data, unless otherwise specified	Apr. 08, 2014	Apr. 30, 2014	Mar. 31, 2015	Sep. 30, 2014	Apr. 08, 2014
Organization, Description of Business, and Summary of Significant Accounting Policies
Shares of common stock sold in IPO		6,874,997
Price at which shares of common stock were sold in IPO (in dollars per share)		$8
Net cash proceeds from the IPO, including proceeds from the partial exercise of the underwriters' option, after underwriting discounts, commissions and issuance costs		$48.50
Shares of common stock issued upon conversion of all outstanding shares of convertible preferred stock	3,567,807
Carrying value of outstanding shares of convertible preferred stock reclassified to common stock and additional paid-in capital					57.3
Shares of common stock issued upon conversion of convertible preferred stock and common stock	971,440
Number of shares repurchased	1,077,809
Aggregate repurchase price	$5.20
Authorized shares (in shares)					155,000,000
Authorized common stock (in shares)			150,000,000	150,000,000	150,000,000
Authorized preferred stock (in shares)			5,000,000	5,000,000	5,000,000
Common stock, par value (in dollars per share)			$0.00	$0.00	$0.00
Preferred stock, par value (in dollars per share)			$0.00	$0.00	$0.00

Organization_Description_of_Bu3

Organization, Description of Business, and Summary of Significant Accounting Policies (Details 2) (USD $)	3 Months Ended		6 Months Ended		0 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Sep. 30, 2014
Revenue Recognition
Royalties and profit sharing	$0.60	$1.10	$1.20	$3
Revenues. | Customer concentration
Concentration of credit risk
Number of partners			4	4
Revenues. | Customer concentration | Four partners
Concentration of credit risk
Concentration risk percentage	89.00%	92.00%	89.00%	94.00%
Accounts receivable | Credit concentration | Four partners
Concentration of credit risk
Concentration risk percentage					71.00%	95.00%

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (Recurring basis, USD $)	Mar. 31, 2015	Sep. 30, 2014
In Thousands, unless otherwise specified
Level I
Financial Assets
Total financial assets	$33,593	$36,019
Level I | Money market funds
Financial Assets
Total financial assets	33,593	36,019
Total
Financial Assets
Total financial assets	33,593	36,019
Total | Money market funds
Financial Assets
Total financial assets	$33,593	$36,019

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (Level III, USD $)	Mar. 31, 2015	Sep. 30, 2014
In Thousands, unless otherwise specified
Carrying Value
Fair value measurements
Long-term debt	$49,024	$38,262
Total	49,024	38,262
Total
Fair value measurements
Long-term debt	49,145	40,357
Total	49,145	40,357
Difference
Fair value measurements
Long-term debt	121	2,095
Total	$121	$2,095

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2015	Sep. 30, 2014
In Thousands, unless otherwise specified
Inventories
Raw materials	$1,700	$1,268
Work in process	850	898
Finished goods	564	632
Total inventories, cost	3,114	2,798
Less inventory reserves	-153	-206
Total inventories, net	$2,961	$2,592

LongTerm_Debt_Details

Long-Term Debt (Details) (USD $)	0 Months Ended		1 Months Ended		6 Months Ended	12 Months Ended
	Dec. 04, 2014	Nov. 14, 2014	Dec. 31, 2012	Aug. 31, 2012	Mar. 31, 2015	Sep. 30, 2014	Nov. 14, 2014	Jul. 13, 2012
					installment
Long-term Debt
Total long-term debt					$49,024,000	$38,262,000
Less current portion					54,000	107,000
Long-term portion					48,970,000	38,155,000
Proceeds from issuance of long-term debt					10,000,000
Term loan agreement expiring on June 30, 2019
Long-term Debt
Total long-term debt					48,421,000	37,625,000
Unamortized discount					66,000	76,000
Interest rate (as a percent)					15.00%
Face amount		45,000,000					45,000,000	35,000,000
Increase in principal amount		10,000,000
Amount drawn			6,000,000	29,000,000
Proceeds from issuance of long-term debt	10,000,000
Number of quarterly installments for repayment of outstanding principal					4
Percentage of cash payment the entity can defer by converting interest due into additional notes		3.50%
Portion of interest due converted into additional notes					3,500,000	2,700,000
Principal amount outstanding					48,500,000
Notes payable due in April 2017
Long-term Debt
Total long-term debt					81,000	96,000
Monthly payments of principal and interest					3,000
Interest rate (as a percent)					7.00%	7.00%
Notes payable due in November 2024
Long-term Debt
Total long-term debt					522,000	541,000
Monthly payments of principal and interest					$6,000
Interest rate (as a percent)					7.00%	7.00%

Collaboration_and_Partner_Arra2

Collaboration and Partner Arrangements (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Collaboration and partner arrangements
Total revenues	$11,291	$10,717	$21,057	$21,185
Collaboration and partner arrangements
Collaboration and partner arrangements
Total revenues	11,291	10,717	21,057	21,185
Collaboration and partner arrangements | P&G
Collaboration and partner arrangements
Total revenues	2,539	2,811	6,216	5,762
Collaboration and partner arrangements | Teva
Collaboration and partner arrangements
Total revenues	3,922	2,784	5,826	6,487
Collaboration and partner arrangements | Par
Collaboration and partner arrangements
Total revenues	2,611	3,405	4,863	6,528
Collaboration and partner arrangements | Agile
Collaboration and partner arrangements
Total revenues	980	851	1,867	1,217
Collaboration and partner arrangements | Other
Collaboration and partner arrangements
Total revenues	$1,239	$866	$2,285	$1,191

Warrants_Details

Warrants (Details) (Common stock warrants, USD $)	0 Months Ended
	Mar. 31, 2015
Warrants
Warrants outstanding (in shares)	128,582
Weighted-average exercise price (in dollars per share)	1.77
Maximum
Warrants
Warrant term	5 years

Convertible_Preferred_Stock_Co1

Convertible Preferred Stock, Common Stock and Stockholders' Equity (Deficit) (Details) (USD $)	Mar. 31, 2015	Sep. 30, 2014	Apr. 08, 2014
Preferred Stock
Authorized preferred stock (in shares)	5,000,000	5,000,000	5,000,000
Preferred stock, par value (in dollars per share)	$0.00	$0.00	$0.00
Preferred stock outstanding (in shares)	0	0
Common Stock
Common shares authorized	150,000,000	150,000,000	150,000,000
Common shares par value (in dollars per share)	$0.00	$0.00	$0.00
Common stock, shares outstanding	18,072,866	18,003,883

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	0 Months Ended		6 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jan. 16, 2015	Mar. 20, 2014	Mar. 31, 2015	Sep. 30, 2014
Stock-based compensation
Number of plans			4	4
2014 Plan
Stock-based compensation
Term of the plan		10 years
Number of shares of common stock initially reserved under plan for issuance to employees		1,000,000
Maximum annual increase in number of shares issuable by the plan, as a percentage of shares outstanding as of the preceding December 31		4.00%
Shares Available for Grant
Additional shares authorized	722,834
Corium Plans
Stock-based compensation
Vesting period			4 years
Assumptions used in estimating weighted average fair value of the options granted
Expected volatility, minimum			70.00%
Expected volatility, maximum			77.00%
Risk-free interest rate, minimum			1.60%
Risk-free interest rate, maximum			1.90%
Expected dividend rate (as a percent)			0.00%
Corium Plans | Minimum
Assumptions used in estimating weighted average fair value of the options granted
Expected term (in years)			5 years 3 months 7 days
Corium Plans | Maximum
Stock-based compensation
Term of the plan			10 years
Assumptions used in estimating weighted average fair value of the options granted
Expected term (in years)			6 years 7 months 17 days
Corium Plans | Stock options
Shares Available for Grant
Balance at the beginning of the period (in shares)			949,885
Additional shares authorized			722,834
Granted (in shares)			-689,950
Forfeited / Cancelled (in shares)			3,785
Balance at the end of the period (in shares)			986,554	949,885
Stock Options Outstanding
Balance at the beginning of the period (in shares)			2,085,028
Granted (in shares)			689,950
Exercised (in shares)			-3,383
Forfeited / Cancelled (in shares)			-3,785
Balance at the end of the period (in shares)			2,767,810	2,085,028
Options exercisable at the end of the period (in shares)			1,458,272
Options vested and expected to vest at the end of the period (in shares)			2,647,448
Weighted Average Exercise Price
Balance at the beginning of the period (in dollars per share)			2.92
Granted (in dollars per share)			5.57
Exercised (in dollars per share)			1.65
Forfeited / Cancelled (in dollars per share)			3.5
Balance at the end of the period (in dollars per share)			3.58	$2.92
Options exercisable at the end of the period (in dollars per share)			2.67
Options vested and expected to vest at the end of the period (in dollars per share)			3.51
Weighted Average Remaining Contractual Life
Balance at the end of the period			7 years 3 months 11 days	7 years 7 days
Options exercisable at the end of the period			5 years 9 months 22 days
Options vested and expected to vest at the end of the period			4 years 2 months 23 days
Aggregate Intrinsic Value
Balance at the end of the period			8,219	$6,710
Options exercisable at the end of the period			5,658
Options vested and expected to vest at the end of the period			8,048
Additional disclosures
Exercise price, minimum(in dollars per share)			2.12
Exercise price, maximum(in dollars per share)			8.18
StrataGent Plan | Stock options | StrataGent, Inc.
Stock-based compensation
Additional shares available for grant assumed by the entity			0
Shares Available for Grant
Balance at the end of the period (in shares)			0

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 2) (USD $)	3 Months Ended		6 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Jan. 16, 2015	Mar. 20, 2014	Sep. 30, 2014
						item
Stock-Based Compensation
Stock-based compensation expense	$676,000	$194,000	$1,364,000	$250,000
Common stock, shares issued	18,072,866		18,072,866				18,003,883
2014 Employee Stock Purchase Plan
Stock-Based Compensation
Number of shares of common stock initially reserved under plan for issuance to employees						310,000
Shares available for issuance	430,952		430,952
Term of the plan						10 years
Maximum annual increase in number of shares issuable by the plan, as a percentage of shares outstanding as of the preceding December 31						1.00%
Maximum number of shares to be issued over the term of the plan						4,000,000
Additional shares authorized					181,994
Offering period						24 months
Number of purchase windows during each offering period						4
Period of purchase windows during each offering period						6 months
Purchase price of common stock of the lower of the fair market value of the Company's common stock (as a percent)						85.00%
Stock-based compensation expense	$111,000		$275,000
Shares issued during the period			61,042
Assumptions used in estimating weighted average fair value of the shares expected to be purchased
Expected volatility, minimum			47.00%
Expected volatility, maximum			51.00%
Risk-free interest rate, minimum			0.07%
Risk-free interest rate, maximum			0.54%
Expected dividend rate (as a percent)			0.00%
Expected term, window one (in months)			6 months
Expected term, window two (in months)			12 months
Expected term, window three (in months)			18 months
Expected term, window four (in months)			24 months
2014 Employee Stock Purchase Plan | Minimum
Assumptions used in estimating weighted average fair value of the shares expected to be purchased
Fair value of common stock	$5.73		$5.73
Grant Price			$4.87
Expected term (in years)			6 months
2014 Employee Stock Purchase Plan | Maximum
Assumptions used in estimating weighted average fair value of the shares expected to be purchased
Fair value of common stock	$8		$8
Grant Price			$6.80
Expected term (in years)			2 years

StockBased_Compensation_Detail2

Stock-Based Compensation (Details 3) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Employee stock-based compensation expense
Stock-based compensation	$676,000	$194,000	$1,364,000	$250,000
Additional Disclosure
Unrecognized employee compensation cost, net of estimated forfeitures	5,200,000		5,200,000
Weighted-average period over which unrecognized compensation cost is expected to be recognized			2 years 10 months 24 days
Cost of product revenues
Employee stock-based compensation expense
Stock-based compensation	82,000	5,000	185,000	11,000
Cost of contract research and development revenues
Employee stock-based compensation expense
Stock-based compensation	46,000	5,000	103,000	9,000
Research and development
Employee stock-based compensation expense
Stock-based compensation	143,000	16,000	268,000	23,000
General and administrative
Employee stock-based compensation expense
Stock-based compensation	$405,000	$168,000	$808,000	$207,000

Product_Recall_Liability_Detai

Product Recall Liability (Details) (USD $)	6 Months Ended	36 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Sep. 30, 2010	Oct. 31, 2012
		item
Product recall liability
Revised combined remaining liability	$3,351		$5,000
Changes to the product recall liability
Beginning balance	3,710		5,000
Payment of settlement liability	-359
Ending balance	$3,351		$5,000
Actavis
Product recall liability
Number of voluntary recalls of certain lots and strengths of Fentanyl TDS		2

Net_Income_Loss_and_Net_Income2

Net Income (Loss) and Net Income (Loss) per Share Attributable to Common Stockholders (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Basic Net income (loss) per share
Net income (loss) attributable to common stockholders, basic and diluted	($7,142)	$3,534	($13,901)	$1,436
Less: undistributed earnings attributable to participating securities		-2,420		-1,375
Net Income (loss) attributable to common stockholders, basic	-7,142	1,114	-13,901	61
Weighted average shares used in computing net income (loss) per share attributable to common stockholders, basic	18,071,320	2,232,300	18,052,809	2,231,049
Net income (loss) attributable to common stockholders, basic (in dollars per share)	($0.40)	$0.50	($0.77)	$0.03
Fully Diluted Net income (loss) per share
Net income (loss) attributable to common stockholders, basic and diluted	-7,142	3,534	-13,901	1,436
Less: undistributed earnings attributable to participating securities		-1,573		-1,358
Net income (loss) attributable to common stockholders, diluted	($7,142)	$1,961	($13,901)	$78
Weighted average shares used in computing net income (loss) per share attributable to common stockholders, basic (in shares)	18,071,320	2,232,300	18,052,809	2,231,049
Effect of potentially dilutive securities
Dilutive options (in shares)		756,300		518,655
Assumed conversion of convertible notes (in shares)		2,063,989
Common stock warrants (in shares)		877,720		733,252
Weighted average shares used in computing net income (loss) per share attributable to common stockholders, basic	18,071,320	5,930,309	18,052,809	3,482,956
Net income (loss) attributable to common stockholders, diluted (in dollars per share)	($0.40)	$0.33	($0.77)	$0.02
Convertible Preferred Stock
Anti-dilutive securities excluded from calculation of diluted net income (loss) per share attributable to common stockholders
Number of anti-dilutive securities excluded from calculation of diluted net income (loss) per share attributable to common stockholders		3,567,807		3,537,807
Stock options
Anti-dilutive securities excluded from calculation of diluted net income (loss) per share attributable to common stockholders
Number of anti-dilutive securities excluded from calculation of diluted net income (loss) per share attributable to common stockholders	2,767,810		2,767,810	37,902
Shares authorized under the 2014 ESPP
Anti-dilutive securities excluded from calculation of diluted net income (loss) per share attributable to common stockholders
Number of anti-dilutive securities excluded from calculation of diluted net income (loss) per share attributable to common stockholders	430,952		430,952
Common stock warrants
Anti-dilutive securities excluded from calculation of diluted net income (loss) per share attributable to common stockholders
Number of anti-dilutive securities excluded from calculation of diluted net income (loss) per share attributable to common stockholders	128,582		128,582
Preferred stock warrants
Anti-dilutive securities excluded from calculation of diluted net income (loss) per share attributable to common stockholders
Number of anti-dilutive securities excluded from calculation of diluted net income (loss) per share attributable to common stockholders		170,962		136,658
Convertible notes
Anti-dilutive securities excluded from calculation of diluted net income (loss) per share attributable to common stockholders
Number of anti-dilutive securities excluded from calculation of diluted net income (loss) per share attributable to common stockholders				2,090,604

Income_Taxes_Details

Income Taxes (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Income Taxes
Income tax expense	$2

Segment_and_EnterpriseWide_Inf1

Segment and Enterprise-Wide Information (Details)	6 Months Ended
	Mar. 31, 2015
	item
Segment and Enterprise-Wide Information
Number of business activities	1
Number of segment managers held accountable for operations, or operating results for levels or components	0